FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years and Older with GEP-NETs
Approval is based on pharmacokinetic, dosimetry, and safety data from NETTER-P study in adolescent patients and also on the extrapolation of efficacy outcomes observed in NETTER-1 study which supported the original approval in adult patients